Kyntheum

Brodalumab, the active ingredient in Kyntheum, is a IL‑17 receptor antagonist presented as a 210 mg/1 mL solution for injection for subcutaneous use. It treats moderate to severe plaque psoriasis in adult patients.

GNH USA supplies Kyntheum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Brodalumab acts on the IL‑17 pathway, which is central to the pathogenesis of plaque psoriasis.

Plaque psoriasis: reduces skin lesions and improves quality of life in patients with moderate to severe disease.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate pain. - Arthralgia: joint pain without swelling. - Injection site reactions: redness, swelling or pain at the injection site. - Fatigue: general tiredness. - Upper respiratory infection: cough, sore throat.

Serious or Rare Side Effects: - Suicidal ideation: new or worsening thoughts of self‑harm. - Depression: mood changes requiring clinical attention. - Serious infections: bacterial, fungal or viral infections requiring treatment. - Allergic reactions: urticaria, angioedema, anaphylaxis. - Neutropenia: low neutrophil count increasing infection risk. - Inflammatory bowel disease exacerbation: worsening of Crohn's disease or ulcerative colitis.

Before initiating therapy, clinicians should assess patient history and monitor during treatment.

Screen for depression: evaluate mental health status and provide counseling. Monitor for suicidal ideation: educate patients to report mood changes promptly. Infection risk: treat active infections before dosing and monitor for new infections. Vaccination: avoid live vaccines during treatment. Pregnancy: safety unknown; weigh risks and benefits before use. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Brodalumab may interact with other immunomodulatory agents and vaccines.

Major Interactions (Avoid): - Concomitant biologics: increased risk of severe infections. - Live vaccines: may cause uncontrolled infection. - Systemic immunosuppressants (high dose): heightened infection susceptibility.

Moderate Interactions (Monitor Closely): - Methotrexate or cyclosporine: monitor for additive immunosuppression. - Antifungal agents: observe for potential infection risk. - Seasonal influenza vaccine (inactivated): timing may be adjusted.